Gufic BioSciences Ltd Share Price

Description

• Gufic Biosciences Ltd. is one of the pharma industry’s most rapidly growing companies. The company is classified as a small-cap company, with a current market capitalisation of Rs. 2,463 crore. The company was incorporated in the year 1984 with its registered office in Mumbai, Maharastra. Some of the key names in the company’s management are Pranav J Choksi, Shreyas K Patel, Rabi N Sahoo, Shrirang V Vaidya, and a few more. As of the third quarter of the financial year 2021-22, Gufic Biosciences’ net income was Rs. 21.04 crore.  Gufic Bio share is listed on both the National Stock Exchange and the Bombay Stock Exchange and is traded under the script name GUFICBIO.

  Gufic Biosciences is in the business and manufacturing of generic medicines, API formulations, and related services. The company operates through different segments such as Criti care, CritiCare life, personal care products, etc. The criti care lineup includes Rabol, Doxific, Tigefic-Plus, etc. The CritiCare life portfolio includes Gufivan-500. The personal care product lineup includes roll-on, stretch-nil, and so on. Whereas; Sulconazole, Micafungin, and Everolimus comes under API segment.

  The Gufic Biosciences’s Price-to-Earning (PE) ratio and Price-to-Book (PB) Ratio stand at 55.69 and 14.20, respectively. The company posted a Return on Earnings (ROE) of 29.22%. The dividend yield of the company is 0.04%. In the three quarters of the financial year 2021-22, the company’s net profit saw a downward trend, with figures of Rs. 31.21 crore, Rs. 23.34 crore, and Rs. 21.03 crore, respectively. In terms of shareholding patterns, promoters increased their position in the September quarter of FY 2021-22, while mutual funds trimmed their holdings slightly.

  On April 4, 2022, Gufic Bio share recorded an open price of Rs. 254.10 and made an intraday high of Rs. 267.80.  Gufic Bio’s share price also performed quite well in the last 12 months and reported 132.48% returns on the price chart. The 52-week high and low of Gufic Biosciences share price were Rs. 270 and Rs. 107.55. The share price of Gufic Biosciences is competing with CIPLA Ltd., Torrent Pharmaceuticals Ltd., Sun Pharmaceuticals Industries Ltd., and Dr Reddy’s Laboratories Ltd. 

  Disclaimer:- ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest.  I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.

• Gufic Biosciences Ltd. is one of the pharma industry’s most rapidly growing companies. The company is classified as a small-cap company, with a current market capitalisation of Rs. 2,463 crore. The company was incorporated in the year 1984 with its registered office in Mumbai, Maharastra. Some of the key names in the company’s management are Pranav J Choksi, Shreyas K Patel, Rabi N Sahoo, Shrirang V Vaidya, and a few more. As of the third quarter of the financial year 2021-22, Gufic Biosciences’ net income was Rs. 21.04 crore.  Gufic Bio share is listed on both the National Stock Exchange and the Bombay Stock Exchange and is traded under the script name GUFICBIO.

  Gufic Biosciences is in the business and manufacturing of generic medicines, API formulations, and related services. The company operates through different segments such as Criti care, CritiCare life, personal care products, etc. The criti care lineup includes Rabol, Doxific, Tigefic-Plus, etc. The CritiCare life portfolio includes Gufivan-500. The personal care product lineup includes roll-on, stretch-nil, and so on. Whereas; Sulconazole, Micafungin, and Everolimus comes under API segment.

  The Gufic Biosciences’s Price-to-Earning (PE) ratio and Price-to-Book (PB) Ratio stand at 55.69 and 14.20, respectively. The company posted a Return on Earnings (ROE) of 29.22%. The dividend yield of the company is 0.04%. In the three quarters of the financial year 2021-22, the company’s net profit saw a downward trend, with figures of Rs. 31.21 crore, Rs. 23.34 crore, and Rs. 21.03 crore, respectively. In terms of shareholding patterns, promoters increased their position in the September quarter of FY 2021-22, while mutual funds trimmed their holdings slightly.

  On April 4, 2022, Gufic Bio share recorded an open price of Rs. 254.10 and made an intraday high of Rs. 267.80.  Gufic Bio’s share price also performed quite well in the last 12 months and reported 132.48% returns on the price chart. The 52-week high and low of Gufic Biosciences share price were Rs. 270 and Rs. 107.55. The share price of Gufic Biosciences is competing with CIPLA Ltd., Torrent Pharmaceuticals Ltd., Sun Pharmaceuticals Industries Ltd., and Dr Reddy’s Laboratories Ltd. 

  Disclaimer:- ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest.  I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.